Innate Pharma Announces First DSMB Review of Ongoing EffiKIR Phase II Trial with lirilumab
Innate Pharma SA (OTC: IPHYF), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the Data and Safety Monitoring Board ("DSMB") completed its first assessment of the EffiKIR study and unanimously recommended continuation of the trial without modification.
The assessment was based on a safety analysis pre-planned for when the first 30 patients would be treated with a minimum of two cycles of therapy.
A DSMB is a committee of independent clinical research experts who review data in ongoing clinical trials with particular attention to safety. DSMBs are customarily established for large randomized multisite studies.
Hervé Brailly, CEO of Innate Pharma, said: "We are very pleased to see that the EffiKIR trial is progressing on track, with this first DSMB review and with more than a third of the patients already accrued".